Archives of the Turkish Society of Cardiology
Serum galectin-3 level predicts early recurrence following successful direct-current cardioversion in persistent atrial fibrillation patients [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2019; 47(7): 564-571 | DOI: 10.5543/tkda.2019.58399

Serum galectin-3 level predicts early recurrence following successful direct-current cardioversion in persistent atrial fibrillation patients

Kadri Murat Gürses1, Muhammed Ulvi Yalçın2, Duygu Koçyiğit3, Hande Canpınar4, Ahmet Hakan Ateş5, Uğur Canpolat5, Hikmet Yorgun5, Dicle Güç4, Kudret Aytemir5
1Department of Basic Medical Sciences, Aydın Adnan Menderes University Faculty of Medicine, Aydın, Turkey
2Department of Cardiology, Selçuk University Faculty of Medicine, Konya, Turkey
3Department of Cardiology, Dinar State Hospital, Afyonkarahisar, Turkey
4Department of Basic Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
5Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey


OBJECTIVE
Atrial structural remodeling has been suggested to contribute to atrial fibrillation (AF) recurrence following direct-current cardioversion (DCCV). The role of several inflammatory and extracellular matrix turnover markers in AF recurrence following DCCV has been investigated. However, data on the impact of galectin-3, which is known to play a role in various fibrotic conditions, including cardiac fibrosis are lacking. The aim of this study was to demonstrate the predictive role of serum galectin-3 levels in AF recurrence following successful DCCV.

METHODS
A total of 90 persistent AF patients who were sche-duled for DCCV were prospectively enrolled. Serum samples were assayed to determine pre-DCCV galectin-3 levels using the enzyme-linked immunosorbent assay method. Patients were followed up for 3 months for AF recurrence.

RESULTS
Of 90 persistent AF patients (mean age: 55.33±7.94 years; 53.33% male) who underwent successful DCCV, 28 (31.11%) experienced early AF recurrence within 3 months. Patients with AF recurrence had a greater left atrial volume index (LAVI) (33.35± 2.45 mL/m2 vs. 29.21±3.08 mL/m2; p<0.001) and serum galectin-3 levels were higher (0.88 ng/mL [min-max: 0.52–1.32] vs. 0.60 ng/mL [min-max: 0.38–0.91]; p<0.001). In multivariate analysis, the number of DCCV attempts (hazard ratio [HR]: 1.879, 95% confidence interval [CI]: 1.052–3.355; p=0.033), LAVI (HR: 1.180, 95% CI: 1.028–1.354; p=0.018), and serum galectin-3 level (HR: 11.933, 95% CI: 1.220–116.701; p=0.033) were found to be independently associated with early AF recurrence following successful DCCV.

CONCLUSION
Circulating levels of galectin-3 may have an association with early AF recurrence following DCCV.

Keywords: Atrial fibrillation, electrical cardioversion; galectin-3; remodeling.

How to cite this article
Kadri Murat Gürses, Muhammed Ulvi Yalçın, Duygu Koçyiğit, Hande Canpınar, Ahmet Hakan Ateş, Uğur Canpolat, Hikmet Yorgun, Dicle Güç, Kudret Aytemir. Serum galectin-3 level predicts early recurrence following successful direct-current cardioversion in persistent atrial fibrillation patients. Turk Kardiyol Dern Ars. 2019; 47(7): 564-571

Corresponding Author: Muhammed Ulvi Yalçın, Türkiye
© Copyright 2019 Archives of the Turkish Society of Cardiology
LookUs & Online Makale